Plain-English translation of ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers are developing better MRI methods to measure the composition of fat tissue surrounding your heart, and testing whether semaglutide—a medication commonly used for diabetes—can change that fat in helpful ways. The study involves people who have heart failure with preserved ejection fraction (a condition where the heart doesn't pump blood out as efficiently as it should, even though the pumping chamber isn't weakened). By understanding the fat around your heart better, doctors hope to find new ways to treat and manage this type of heart failure.
Heart failure with preserved ejection fraction is common and difficult to treat, and doctors don't fully understand what causes it or how to best help patients. Recent research suggests that fat tissue around the heart may play an important role, and the medication being tested is known to help with weight and metabolism—so researchers want to see if it might also help the heart in this condition.
You likely qualify if…
You likely don't qualify if…
You will have heart MRI scans, heart ultrasounds, electrocardiograms (EKGs), blood tests, and a physical exam. Then you'll start taking the medication for 6 months while having repeat imaging tests at the 3-month and 6-month marks to see how the treatment affects the fat around your heart and your heart function. Some visits may include optional stress heart imaging. The entire study takes about 6–9 months from start to finish.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States